FindTrial
Sign In

a pilot study into the effects and feasibility of the use of Tiscover® (tissue-engineered autologous skin substitute) for chronic ulcers (venous ulcers, diabetic ulcers and decubitus ulcers).

a pilot study into the effects and feasibility of the use of Tiscover® (tissue-engineered autologous skin substitute) for chronic ulcers (venous ulcers, diabetic ulcers and decubitus ulcers). - Effects of Tiscover® on chronic ulcers

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON30845
Enrollment
20
Registered
2007-11-13
Start date
2007-03-01
Completion date
Unknown
Last updated
2024-05-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

decubitus/diabetic/ venous ulcers

Interventions

application of an autologous tissue engineered skin substitute

Sponsors

Vrije Universiteit Medisch Centrum
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: · Venous ulcer, arterio(lo)sclerotic ulcer , decubitus ulcer or diabetic ulcer . · chronic (>1 month no tendency to heal), · Ulcer 1-100 cm² · consent (competent) · Ulcus depth

Exclusion criteria

Exclusion criteria: - serious comorbidity (lief expectancy

Design outcomes

Primary

MeasureTime frame
% decrease of ulcer—

Secondary

MeasureTime frame
pain, quality of life, satisfaction patient and caregivers—

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)